study. Both the treatment and control groups displayed further reductions in MASI score as treatment duration continued. Additional studies are needed to evaluate whether melasma recurs once oral TXA is discontinued, or how long maintenance therapy should be continued if needed.
DISCLOSURES
There are no conflicts of interest to disclose.
REFERENCES
1. Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg. 2018;44(6):814-825.
2. Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017;97(7):776-781.
3. Cassiano D, Esposito ACC, Hassun K, et al. Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: An open, evaluator-blinded, randomized clinical trial. J Am Acad Dermatol. 2020;83(4):1176-1178.
4. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):520.
2. Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017;97(7):776-781.
3. Cassiano D, Esposito ACC, Hassun K, et al. Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: An open, evaluator-blinded, randomized clinical trial. J Am Acad Dermatol. 2020;83(4):1176-1178.
4. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60(5):520.
AUTHOR CORRESPONDENCE
Alexandra Rubin MBS alirubin@rwjms.rutgers.edu
